Key result
Higher plasma pentraxin-3 levels are linked to ~27% lower metabolic syndrome risk vs lowest levels.
Why the study?
The role of pentraxin-3 (PTX3) in atherosclerosis remained unclear.
Are higher plasma pentraxin-3 (PTX3) levels associated with improved lipid profiles and lower cardiovascular risk in a general population without lipid-lowering medication?
Cross-Sectional (n=1,747)
Are higher plasma pentraxin-3 (PTX3) levels associated with improved lipid profiles and lower cardiovascular risk in a general population without lipid-lowering medication?
Odds Ratio: 0.73 (95% CI 0.57–0.94)
p-value: p=0.044
Higher circulating PTX3 levels are inversely associated with metabolic syndrome and dyslipidemia, suggesting a potential cardioprotective role in atherosclerosis.
AIM: To elucidate the role of pentraxin-3 (PTX3) in atherosclerosis, we evaluated lipid and cardiovascular risk profiles according to the plasma PTX3 levels in subjects from the general population. METHODS: A sub-cohort of 2,000 subjects was randomly sampled from a Korean community-based cohort study. After excluding those with a medication history for dyslipidemia, 1,747 subjects (902 men and 845 women) were included in the final analyses. Linear and logistic regressions with adjustment for appropriate variables were performed. RESULTS: The PTX3 level was positively associated with the high-density lipoprotein cholesterol (HDL-C) level and negatively associated with the log-transformed triglyceride (TG) level, total cholesterol/HDL-C ratio, and low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio (p＜0.05). Subjects with the highest PTX3 levels (≥ 1.17 ng/dl) exhibited a lower risk of metabolic syndrome (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.57-0.94), overweight/obesity (OR 0.65, 95% CI 0.50-0.83), increased TG level (OR 0.66, 95% CI 0.51-0.86), and increased HDL-C level (OR 0.67, 95% CI 0.51-0.88) compared to those with the lowest PTX3 level (＜0.7 ng/dl). CONCLUSION: The circulating PTX3 level was inversely associated with metabolic syndrome, overweight/obesity, and parameters of dyslipidemia, suggesting a cardioprotective role of PTX3 in atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2019) conducted a cross-sectional in General population without dyslipidemia medication history (n=1,747). Plasma Pentraxin-3 (PTX3) level vs. Lowest PTX3 level tertile (<0.7 ng/dl) was evaluated on Risk of metabolic syndrome (OR 0.73, 95% CI 0.57-0.94, p=0.044). Higher plasma pentraxin-3 levels (≥ 1.17 ng/dl) were significantly associated with a lower risk of metabolic syndrome (OR 0.73) compared to the lowest levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: